End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
4.94
CNY
|
+0.41%
|
|
+0.61%
|
-2.18%
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,806
|
12,156
|
12,979
|
12,569
|
-
|
-
|
Enterprise Value (EV)
1 |
15,806
|
12,156
|
12,979
|
12,569
|
12,569
|
12,569
|
P/E ratio
|
-47.3
x
|
33.8
x
|
22
x
|
16.1
x
|
13.6
x
|
12
x
|
Yield
|
-
|
-
|
3.96%
|
2.83%
|
3.14%
|
-
|
Capitalization / Revenue
|
-
|
-
|
1.93
x
|
1.62
x
|
1.39
x
|
1.27
x
|
EV / Revenue
|
-
|
-
|
1.93
x
|
1.62
x
|
1.39
x
|
1.27
x
|
EV / EBITDA
|
-
|
-
|
11.6
x
|
8.71
x
|
7.82
x
|
7.09
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
1.84
x
|
1.68
x
|
1.56
x
|
1.3
x
|
Nbr of stocks (in thousands)
|
2,570,037
|
2,570,037
|
2,570,037
|
2,544,332
|
-
|
-
|
Reference price
2 |
6.150
|
4.730
|
5.050
|
4.940
|
4.940
|
4.940
|
Announcement Date
|
4/28/20
|
4/11/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
6,733
|
7,756
|
9,015
|
9,918
|
EBITDA
1 |
-
|
-
|
1,116
|
1,443
|
1,606
|
1,772
|
EBIT
1 |
-
|
-
|
788.3
|
1,058
|
1,307
|
1,447
|
Operating Margin
|
-
|
-
|
11.71%
|
13.65%
|
14.5%
|
14.59%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
767.7
|
1,044
|
1,290
|
1,432
|
Net income
1 |
-345.6
|
358.1
|
591.6
|
782.4
|
927.4
|
1,062
|
Net margin
|
-
|
-
|
8.79%
|
10.09%
|
10.29%
|
10.71%
|
EPS
2 |
-0.1300
|
0.1400
|
0.2300
|
0.3067
|
0.3633
|
0.4100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.2000
|
0.1400
|
0.1550
|
-
|
Announcement Date
|
4/28/20
|
4/11/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
1,549
|
1,824
|
1,794
|
1,829
|
1,965
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
107.1
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.0420
|
-0.0100
|
0.0840
|
0.0700
|
0.0600
|
0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/27/23
|
4/19/24
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
8.45%
|
10.1%
|
11.6%
|
10.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
6.6%
|
7.3%
|
-
|
Assets
1 |
-
|
-
|
-
|
11,855
|
12,705
|
-
|
Book Value Per Share
2 |
-
|
-
|
2.740
|
2.940
|
3.180
|
3.810
|
Cash Flow per Share
2 |
-
|
-
|
0.3500
|
0.2500
|
0.4400
|
0.5400
|
Capex
1 |
-
|
-
|
113
|
676
|
676
|
-
|
Capex / Sales
|
-
|
-
|
1.68%
|
8.72%
|
7.5%
|
-
|
Announcement Date
|
4/28/20
|
4/11/23
|
4/19/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -2.18% | 1.74B | | +19.98% | 43.48B | | +20.67% | 22.65B | | +14.56% | 14.73B | | +44.72% | 12.04B | | -8.37% | 7.08B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.47B | | -2.27% | 4.81B |
Generic Pharmaceuticals
|